The new findings position Lilly to file an application for the highly anticipated medicine, but also leave some questions ...

The decision to no longer seek approval of amlitelimab is the latest setback for a treatment once hailed as a future ...

The startup is the first gene editing company to price an IPO in more than two years, though it banked far less than most ...

In a victory for Robert F. Kennedy Jr.’s “MAHA” agenda, panelists narrowly recommended broader use of four peptides despite a ...

Bristol Myers is the third pharmaceutical company to recently seek Nvidia’s help building a large AI data center. Elsewhere, ...

While the possibility of levies on branded pharmaceuticals have had a limited impact on drugmaker revenues, tariffs of up to ...

The young venture firm, which has bet heavily on tech and biotech’s convergence, has now invested in 35 companies and ...

The lawsuit follows a cease-and-desist request and argues Lilly is using “deceptive” ads to claim its GLP-1 products are ...

Analysts expect new details on the lead-up to the deal “are likely to reignite” investor scrutiny that Vertex overpaid in ...

Tempus AI’s planned acquisition follows recent interest in blood-based cancer tests across the medtech industry.

To analysts, the drug’s apparent safety and effects on both triglyceride levels and pancreatitis cases should make it ...

The clearance is GSK’s first for a lung cancer medicine and the latest step forward in a yearslong push by the British ...